Cyclin-dependent kinase 2

Cyclin-dependent kinase 2 (CDK2) is a crucial protein that plays a significant role in the regulation of the cell cycle, facilitating the transition from the G1 phase to the S phase and the progression through the S phase. As a member of the Cyclin-dependent kinase family, CDK2 is essential for cellular replication and division, making it a key focus in the study of cancer and other proliferative diseases.

Function[edit | edit source]

CDK2 forms complexes with specific regulatory proteins called cyclins, particularly Cyclin E during the G1 to S phase transition and Cyclin A during the S phase. These complexes are vital for the progression of the cell cycle through phosphorylation of target substrates, leading to DNA replication and cell division. The activity of CDK2 is tightly regulated by cyclins and CDK inhibitors, which ensure the cell cycle progresses at the correct time and maintains genomic integrity.

Regulation[edit | edit source]

The activity of CDK2 is controlled at multiple levels, including the binding of cyclins, phosphorylation, and the interaction with CDK inhibitors. Cyclin E binds to CDK2 at the G1/S transition, activating the kinase. Subsequently, Cyclin A binds to CDK2 during the S phase, maintaining its activity. The anaphase-promoting complex (APC) degrades cyclins at specific points in the cell cycle, leading to the inactivation of CDK2 and ensuring proper cell cycle progression. Additionally, phosphorylation at specific residues on CDK2 modulates its activity, while CDK inhibitors such as p21 and p27 can bind to and inhibit CDK2, preventing premature progression of the cell cycle.

Clinical Significance[edit | edit source]

Given its pivotal role in cell cycle regulation, CDK2 is a target for cancer therapy. Aberrant activity of CDK2, often due to overexpression of cyclins or loss of CDK inhibitors, is associated with uncontrolled cell proliferation, a hallmark of cancer. Inhibitors of CDK2 are being developed and tested for their potential to halt the progression of tumors by arresting cells in the G1 phase or preventing DNA replication. These inhibitors represent a promising avenue for cancer treatment, aiming to specifically target tumor cells while sparing normal cells.

Research[edit | edit source]

Research on CDK2 spans from understanding its basic biology and regulation in the cell cycle to exploring its role in diseases and developing targeted therapies. Studies using genetic knockout models, small molecule inhibitors, and monoclonal antibodies are advancing our knowledge of CDK2's functions and its potential as a therapeutic target. Ongoing clinical trials are evaluating the efficacy and safety of CDK2 inhibitors in various cancer types, with the hope of providing new treatments for patients.